Laboratory Developed Tests Market Size & Growth Forecast 2026–2035, By Segments (Technology, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Laboratory Developed Tests Market size was worth USD 13.87 Billion in 2025 and is expected to grow at a 7.1% CAGR between 2026 and 2035, crossing USD 27.54 Billion by 2035. The industry revenue for 2026 is calculated at USD 14.73 billion.
Get more details on this report
Request Free Sample ReportLaboratory Developed Tests Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 39.78% of the market in 2025 due to its advanced laboratory infrastructure, strong molecular testing capabilities, and widespread use of specialized diagnostics across clinical care settings.
- Asia Pacific is expected to grow at an 8.02% CAGR as healthcare systems expand laboratory capabilities, increase molecular testing adoption, and improve access to specialized diagnostic services.
Segment Momentum
- Oncology held a 23.92% share in 2025 because laboratories rely on highly tailored testing for cancer detection, characterization, and treatment monitoring, sustaining strong demand for specialized diagnostic solutions.
- Immunoassays are the fastest-growing technology segment as laboratories adopt scalable, workflow-friendly testing methods that support broad biomarker detection with greater operational flexibility.
Market Expansion Drivers
- Rising cancer and genetic disorder burden accelerating laboratory developed diagnostic demand.
- Expansion of personalized medicine and precision oncology driving advanced test utilization.
- AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Top companies in the laboratory developed tests market include Illumina, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics Incorporated (United States), Abbott Laboratories (United States), Siemens Healthineers AG (Germany), QIAGEN N.V. (Germany), Guardant Health, Inc. (United States), NeoGenomics, Inc. (United States), Thermo Fisher Scientific Inc. (United States), Exact Sciences Corporation (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
Growing incidence of cancer and inherited disorders is pushing clinicians to seek faster, more tailored diagnostic answers than standardized assays often provide, driving demand for the laboratory developed tests market. Hospitals, oncology centers, and specialty reference labs increasingly rely on laboratory developed tests to detect rare mutations, stratify disease subtypes, and support treatment selection when commercially available kits do not cover the needed biomarkers or lack sufficient flexibility. This dynamic is driving market development as laboratories invest in disease-specific panels, expand molecular testing menus, and integrate more complex workflows that respond to rising volumes of patients requiring earlier and more precise diagnostic assessment.
Expansion of personalized medicine and precision oncology driving advanced test utilization
As treatment decisions become more closely tied to individual biomarker profiles, the laboratory developed tests market is gaining momentum from the need for assays that can match specific clinical questions, sample types, and therapeutic pathways. Precision oncology in particular is increasing market penetration for multi-gene panels, companion-style testing approaches, and longitudinal monitoring assays because laboratories need the ability to update targets quickly as new therapies and resistance markers emerge. That flexibility is influencing market adoption among providers and health systems that prefer laboratory developed tests when they need clinically actionable results beyond the scope of fixed-format diagnostics.
AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency
AI-supported sequencing analysis and laboratory automation are reshaping operating economics in the laboratory developed tests market by reducing interpretation bottlenecks, improving workflow consistency, and enabling higher sample throughput without proportional increases in manual labor. In practice, this allows molecular laboratories to process more complex datasets, shorten turnaround times, and scale specialized testing services that were previously constrained by staffing intensity and analytical complexity. The result is stronger market expansion as providers become more willing to adopt advanced laboratory developed tests when delivery becomes faster, more reproducible, and better aligned with routine clinical decision timelines.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cancer and genetic disorder burden accelerating laboratory developed diagnostic demand | 2.20% | High | North America, Europe | High | Near Term |
| Expansion of personalized medicine and precision oncology driving advanced test utilization | 2.00% | High | North America, Europe, Asia Pacific | High | Mid Term |
| AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency | 1.60% | Moderate | North America, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 39.78% share of the laboratory developed tests market in 2025, bolstered by the region’s established clinical laboratory infrastructure, broad availability of advanced molecular and genetic testing capabilities, and strong integration of specialized diagnostics into routine care pathways. Demand remains concentrated in settings where hospitals, reference labs, and academic medical centers can rapidly develop and validate tests for oncology, infectious disease, rare disease, and precision medicine applications. This operating environment helps sustain regional leadership because laboratories have the technical depth, installed instrumentation, and clinician access needed to move from assay development to regular clinical use efficiently.
Asia Pacific is projected to expand at an 8.02% CAGR over the forecast period in the laboratory developed tests market, driven by rising adoption of advanced diagnostics across large patient populations and the ongoing buildout of laboratory capabilities in major healthcare systems. Growth is accelerating as providers increasingly use locally developed assays to address unmet testing needs, improve turnaround times, and broaden access to specialized diagnostics beyond top-tier urban centers. The region’s momentum is also reinforced by expanding use of molecular testing in disease detection and treatment selection, which is translating into stronger utilization of laboratory-developed offerings in day-to-day clinical practice.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality Diagnostic StandardsGermany emphasizes laboratory developed tests that support precision diagnostics while maintaining rigorous analytical validation and quality requirements. German laboratories continue expanding advanced molecular testing capabilities across oncology, infectious diseases, and genetic diagnostics.
France 🇫🇷
Specialized Diagnostic ServicesFrance supports laboratory developed tests through collaboration between hospital laboratories, research institutions, and diagnostic developers. French laboratories continue refining specialized assays that address complex clinical conditions while supporting broader adoption of precision healthcare.
Italy 🇮🇹
Laboratory Capacity EnhancementItaly is strengthening laboratory developed tests by modernizing diagnostic infrastructure and expanding access to advanced molecular testing. Clinical laboratories in Italy emphasize standardized workflows, improved analytical performance, and specialized testing services for complex disease management.
Japan 🇯🇵
Clinical Testing InnovationJapan prioritizes laboratory developed tests that enhance diagnostic precision and support individualized treatment decisions. Healthcare providers in Japan increasingly adopt advanced molecular technologies and automated laboratory workflows to improve testing efficiency and clinical utility.
South Korea 🇰🇷
Molecular Testing CapabilitySouth Korea is expanding laboratory developed tests through investments in advanced clinical laboratories and biotechnology innovation. Organizations strengthen genomic testing capabilities and specialized diagnostic services to support precision medicine across multiple therapeutic areas.
United States 🇺🇸
Precision Diagnostics ExpansionThe U.S. laboratory developed tests market continues evolving through increasing demand for personalized medicine, molecular diagnostics, and specialized clinical testing. Laboratories in the U.S. invest in advanced assay development, automation, and data analytics to improve diagnostic accuracy and efficiency.
Segment Leadership and Growth Trends
Laboratory Developed Tests Market Share (%), Technology, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportMolecular Diagnostics held a 27.79% share of the laboratory developed tests market in 2025, making it the leading technology segment. Its position is sustained by the practical role these tests play in detecting genetic, infectious, and disease-specific biomarkers with high analytical relevance for clinical decision-making. In the laboratory developed tests market, molecular diagnostics remains widely used because laboratories rely on it when precision, customization, and the ability to support complex case stratification are central to test design and adoption.
Immunoassays are emerging as the fastest-growing technology segment in the laboratory developed tests market as laboratories seek scalable testing approaches that can support broad clinical use with efficient workflow integration. Their momentum is tied to expanding demand for targeted protein and biomarker detection across routine and specialized settings, where turnaround needs and operational adaptability matter. Compared with more technically intensive alternatives, immunoassays are seeing wider adoption because they fit more readily into evolving lab requirements for accessible, application-flexible test development.
Application Segment Analysis: Oncology (Largest Segment) vs Nutritional & Metabolic Disease (Fastest-Growing Segment)
In 2025, Oncology accounted for a 23.92% share of the laboratory developed tests market, securing its place as the largest application segment. This leadership reflects the sustained need for highly tailored testing in cancer detection, characterization, and treatment monitoring, where laboratory developed tests are often used to address clinically specific biomarker requirements. The oncology segment continues to lead the laboratory developed tests market because disease complexity and the need for individualized diagnostic insight keep demand concentrated in this application area.
Nutritional & Metabolic Disease is the fastest-growing application segment in the laboratory developed tests market, backed by rising attention to condition-specific assessment that often requires more customized testing than standardized panels can provide. Growth is being encouraged by the practical need to evaluate diverse metabolic markers and nutritional imbalances with greater specificity across varied patient profiles. Relative to more established applications, this segment is gaining momentum as laboratories expand into areas where personalized assessment and flexible assay development are becoming more relevant to clinical practice.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology | Immunoassays, Hematology & Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy, Others | Molecular Diagnostics | Immunoassays |
| Application | Oncology, Genetic Disorders/Inherited Disease, Infectious & Parasitic Diseases, Immunology, Endocrine, Nutritional & Metabolic Disease, Cardiology, Mental/Behavioral Disorder, Pediatrics-specific Testing, Hematology/General Blood Testing, Bodily Fluid Analysis, Toxicology, Others | Oncology | Nutritional & Metabolic Disease |
Competitive Landscape and Market Positioning
1. Illumina Inc. (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Quest Diagnostics Incorporated (United States)
4. Abbott Laboratories (United States)
5. Siemens Healthineers AG (Germany)
6. QIAGEN N.V. (Germany)
7. Guardant Health Inc. (United States)
8. NeoGenomics Inc. (United States)
9. Thermo Fisher Scientific Inc. (United States)
10. Exact Sciences Corporation (United States)
The laboratory developed tests market is expanding due to increasing demand for personalized diagnostics and advanced clinical testing. Innovation in testing methodologies is improving diagnostic accuracy. The laboratory developed tests market is also influenced by regulatory frameworks guiding test validation and deployment.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Plus Therapeutics | Aug-25 | Plus Therapeutics secured College of American Pathologists (CAP) accreditation for its CNSide Diagnostics clinical laboratory. This milestone, which complements existing CLIA certification, enhances the firm’s quality assurance framework and supports the commercial rollout of its CNSide cerebrospinal fluid assay platform within the specialized central nervous system diagnostic testing market. |
| PrecisionLife & Ovation.io | Aug-25 | PrecisionLife and Ovation.io announced a collaboration to develop laboratory-developed and direct-to-consumer genetic tests tailored to predict patient responses to GLP-1 therapies. This initiative underscores the increasing convergence of precision medicine and predictive diagnostics, aiming to optimize therapeutic matching and improve clinical outcomes through data-driven genomic testing. |
| Becton Dickinson | Jul-25 | Becton Dickinson expanded its BD MAX diagnostic platform menu in Europe by integrating two IVDR-certified Viasure assays. This enhancement strengthens the company’s molecular diagnostics portfolio under stringent European regulatory standards, promoting greater clinical adoption of automated, high-throughput laboratory testing solutions for infectious disease management. |
| Roche | Jul-25 | Roche launched updated cobas 6800/8800 version 2.0 systems and associated software following recent regulatory clearance. These upgrades significantly improve high-throughput molecular testing performance and workflow efficiency, reinforcing the company’s competitive position in providing automated laboratory infrastructure for infectious disease and clinical diagnostic applications. |
| Pictor | Jul-25 | Pictor established its U.S. headquarters in California, a strategic move to accelerate the commercialization of its multiplex proteomics diagnostic platform. The expansion increases the availability of the company’s high-performance testing technology in the North American market and strengthens its operational footprint within the life sciences diagnostics ecosystem. |
| LabGenomics USA | Jun-25 | LabGenomics USA expanded its U.S. clinical diagnostics network through the acquisition of Integrated Molecular Diagnostics laboratories. By increasing its portfolio to four CLIA-certified facilities, the company has significantly bolstered its laboratory testing capacity and enhanced its ability to scale molecular diagnostic services across the domestic clinical market. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Laboratory Developed Tests Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Laboratory Developed Tests Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow big is the laboratory developed tests market?
What is the expected industry size of laboratory developed tests by 2035?
How is the shift toward precision oncology and personalized medicine driving adoption in the laboratory developed tests market?
How are AI-enabled sequencing and laboratory automation improving efficiency in the laboratory developed tests market?
Why is Oncology the largest application segment in the laboratory developed tests market?
Which technology segment is growing the fastest in the laboratory developed tests market?
Why is North America the leading laboratory developed tests market?
What is driving laboratory developed tests market growth in Asia Pacific?
Who are the major participants shaping the laboratory developed tests landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization